基于深度学习的PSMA PET分割可重复性:一项单中心前瞻性测试-再测试试验的事后分析
本研究为单中心前瞻性测试-再测试试验的事后分析,纳入17例转移性前列腺癌患者,随机分为同一示踪剂组(n=9)和不同示踪剂组(n=8),用全自动AI方法分割PSMA PET影像并量化四种影像生物标志物的受试者水平可重复性。结果显示不同示踪剂组所有生物标志物可重复性较差;同一示踪剂组中AI衍生的PSMA阳性肿瘤体积在高体积病变患者(≥中位肿瘤体积)的可重复系数为13.8%;AI模型在[68Ga]Ga-PSMA-11与[18F]F-PSMA-1007 PET扫描间的病灶水平阳性预测值无显著差异(0.88,IQR 0.69-1.00 vs. 0.78,IQR 0.54-1.00,p=0.60)。结论认为同一示踪剂下AI计算的PSMA阳性肿瘤体积可重复性限度与RECIP 1.0标准用于高体积病变患者相一致,不同示踪剂组可重复性限度显著更宽,提示疗效评估应使用同一放射性示踪剂。
要点
- 不同示踪剂组所有影像生物标志物可重复性均较差。
- 同一示踪剂组高体积病变患者AI衍生PSMA阳性肿瘤体积可重复系数为13.8%。
- AI模型病灶水平阳性预测值在两种示踪剂间无显著差异(p=0.60)。
核心结论
- 同一示踪剂下AI计算的PSMA阳性肿瘤体积可重复性限度与RECIP 1.0标准用于高体积病变患者一致;不同示踪剂组可重复性限度显著更宽,提示疗效评估应使用同一放射性示踪剂。
研究设计与样本
- 单中心前瞻性测试-再测试试验的事后分析,纳入17例转移性前列腺癌患者,随机分为同一示踪剂组(n=9)和不同示踪剂组(n=8),使用全自动AI方法和半自动方法分割扫描。
诊断标准与关键数值
- 同一示踪剂组高体积病变患者(≥中位肿瘤体积)AI衍生PSMA阳性肿瘤体积可重复系数为13.8%。
临床应用与阅片要点
- 作者认为疗效评估应使用同一放射性示踪剂。
局限性
- 本研究为单中心、前瞻性测试-再测试试验的事后分析。
- 样本量为17例转移性前列腺癌患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The primary aim of this study was to quantify the subject-level test-retest repeatability of artificial intelligence (AI)-derived PSMA PET imaging biomarkers using a previously developed model. The secondary aim was to assess the performance of this segmentation model, which was trained on [68 Ga]Ga-PSMA-11 PET scans, on [18F]F-PSMA-1007 PET scans.
METHODS: This was a post-hoc analysis of a prospective, single-center, test-retest trial. Seventeen patients with metastatic prostate cancer (mPCa) were randomised into groups, either receiving the same tracer ([68 Ga]Ga-PSMA-11 or [18F]F-PSMA-1007) for both scans (intra-tracer group, n = 9) or a different tracer (inter-tracer group, n = 8). Scans were delineated using a fully automated AI method and semi-automatically. The subject-level repeatability of four imaging biomarkers, including PSMA-positive tumour volume, was quantified.
RESULTS: Repeatability analysis demonstrated poorer repeatability for all biomarkers in the inter-tracer group. In the intra-tracer group, the AI-derived PSMA-positive tumour volume had a repeatability coefficient of 13.8% for higher volume disease patients (≥ median tumour volume). There was no significant difference in the per-scan lesion-level positive predictive value of the AI model between [68 Ga]Ga-PSMA-11 and [18F]F-PSMA-1007 PET scans (0.88, IQR 0.69-1.00 vs. 0.78, IQR 0.54-1.00, p = 0.60).
CONCLUSION: AI-based PSMA-positive tumour volume calculations have repeatability limits that are consistent with the use of the Response Evaluation Criteria in PSMA PET/CT (RECIP 1.0) criteria for higher volume disease patients when the same tracer is used. Substantially wider repeatability limits in the inter-tracer group provide evidence that response assessment should be conducted using the same radiotracer.
引用
- Kendrick J, Francis RJ, Hassan GM, et al. Deep learning-based PSMA PET segmentation repeatability: A post-hoc analysis of a single-center, prospective, test-retest trial. Radiol Med. 2025. PMID: 41166032. doi:10.1007/s11547-025-02137-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。